Literature DB >> 32546439

Persistence of SARS-CoV-2 virus RNA in feces: A case series of children.

Wenjun Du1, Jinhong Yu1, Xiaoyan Liu2, Hong Chen3, Lingbo Lin4, Qiang Li5.   

Abstract

AIMS: To determine how long SARS-CoV-2 virus RNA persists in fecal specimens in children with COVID-19.
METHODS: Retrospectively, ten children with confirmed COVID-19 in the Jinan Infectious Disease Hospital Affiliated to Shandong University were enrolled between January 23, 2020 to March 9, 2020. Epidemiological, clinical, laboratory, and radiological characteristics of the children were analyzed. RT-PCR assays were performed to detect the SARS-CoV-2 virus RNA in the respiratory tract and fecal specimens in the follow-up after discharge.
RESULTS: Among ten patients, five (50%) were asymptomatic and five (50%) showed mild symptoms of respiratory illness. The average age of asymptomatic children was younger than that of symptomatic children (p = 0.03). The decreases in white blood cell (WBC) (p = 0.03) and lymphocyte (p = 0.03) counts were more severe in symptomatic patients than those in asymptomatic patients. During the follow-up examination after discharge, seven out of ten patients contained SARS-CoV-2 virus RNA in their fecal specimens, despite all patients showed negative results in respiratory tract specimens. One out of those seven patients relapsed. The median time from onset to being negative results in respiratory tract and fecal specimens was 9 days and 34.43 days, respectively.
CONCLUSIONS: SARS-CoV-2 virus RNA persists much longer in the gastrointestinal (GI) tract than that in respiratory tract.
Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  COVID-19; Children; Fecal specimen; SARS-CoV-2

Mesh:

Substances:

Year:  2020        PMID: 32546439      PMCID: PMC7275988          DOI: 10.1016/j.jiph.2020.05.025

Source DB:  PubMed          Journal:  J Infect Public Health        ISSN: 1876-0341            Impact factor:   3.718


Introduction

Since the first atypical pneumonia case was reported in Wuhan, China on December 31, 2019 [1], the viral pathogen was quickly identified as a novel coronavirus by deep sequencing of viral genome (http://virological.org/ and https://www.gisaid.org/) [2]. On February 11, 2020, the World Health Organization officially named the new virus as SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus2) and the disease caused by SARS-CoV-2 infection as COVID-19 (Coronavirus Disease 2019) [3]. The COVID-19 pandemic quickly spread in China and other countries and represents a severe global health threat. According to the Chinese Clinical Guidance for COVID-19 Pneumonia Diagnosis and Treatment (7th version) [4], discharge criteria are defined as: (1) temperature returned to a normal level for more than 3 days; (2) respiratory symptoms significantly improved; (3) pulmonary imaging showed significant improvement in acute exudative lesions; (4) two consecutive virus RNA tests in sputum, nose swab and other respiratory tract specimens showing negative results (sampling should be at least 24 h apart). In this retrospective study, we performed follow-up virus RNA tests on ten children with COVID-19 within 2 weeks after discharge and obtained negative results in the respiratory tract specimens and urine samples from all of them. In sharp contrast, we discovered that seven of them contained SARS-CoV-2 virus RNA in fecal specimens. One male patient with a positive result in fecal specimen test relapsed after discharge and showed progressive clinical symptoms including fever, cough, nausea, vomiting and diarrhea. In sum, these findings indicate that for children with COVID-19, SARS-CoV-2 virus RNA persists longer in GI tract than that in respiratory tract and urine.

Methods

Human subjects

The present study is a retrospective descriptive clinical study. A total of ten children with confirmed COVID-19 in the Jinan Infectious Disease Hospital Affiliated to Shandong University were enrolled in this study between January 23, 2020 to March 9, 2020. This study has been approved by the ethics board of the Jinan Infectious Diseases Hospital Affiliated to Shandong University (No.20200203). Informed consent was obtained from each patient or their guardians. Diagnosis of patients was based on the Chinese Clinical Guidance for COVID-19 Pneumonia Diagnosis and Treatment (7th version) [4]. Diagnostic criteria for asymptomatic cases include: individuals infected by SARS-CoV-2 who remain asymptomatic throughout the course of the infection with or without abnormal chest computed tomography (CT) findings. Diagnostic criteria for mild cases: mild clinical symptoms, no radiographic findings of pneumonia; for regular cases: fever, respiratory symptoms, and radiographic manifestations of pneumonia; for severe cases: (1) respiratory distress, respiratory frequency ≥30 times/min, (2) hypoxemia with resting oxygen saturation ≤93%, and (3) arterial partial oxygen pressure (PaO2)/oxygen absorption concentration (FiO2) ≤300 mmHg (1 mmHg = 0.133 kPa); for critical cases: (1) respiratory failure and mechanical ventilation is required, (2) shock, and (3) complication with other organ failure requiring ICU care.

Data collection

The medical records of patients were collected and analyzed, including demographic data, exposure history, symptoms, signs, laboratory findings, and chest CT scanning. Data collection forms from electronic medical records were used to collect data. Disease onset was defined as the day when the symptom was noticed.

RT­PCR

Respiratory tract and fecal specimens were collected from each patient. SARS-CoV-2 virus RNA was detected by RT-PCR assay using the Dual-target Detection Kit from the Shanghai Jienuo Company. For RT-PCR assay, the cut-off value was 40. A cycle threshold (Ct) value less than 37 was defined as positive.

Statistical analysis

Collected data were recorded into Microsoft Excel for Macintosh (version 16.30).Statistical analysis was carried out with Statistical Package for Social Sciences (SPSS) (version 16.0) and Prism (version 5.0) for Macintosh. Measurement data were described as mean ± standard deviation. Background factors were compared using the Student’s t-test (numerical data) or the Chi-square test (categorical data). In all tests, p values of less than 0.05 were considered statistically significant.

Results

Retrospective analysis of patients with COVID-19

A total of ten children (three male and seven female) were enrolled in this study, with a median age of 5.08 years (range, 9 month-14 years). All the children were in familial clusters. One child (10%) was diagnosed as mild case and nine (90%) as regular cases. Clinical symptoms were mild or even absent, four (40%) children showed fever, two children (20%) experienced dry cough, and one child (10%) had phlegm. Among these ten patients, five (50%) were asymptomatic and five (50%) showed mild symptoms of respiratory illness, including two asymptomatic females (40%) with a median age of 2.36 years and five symptomatic females(100%) with a median age of 7.80 years. The average age of asymptomatic children was younger than that of symptomatic children (p = 0.03) (Table 1 ). Laboratory tests showed that the decreases in white blood cell (WBC) (p = 0.03) and lymphocyte (p = 0.03) counts were more severe in symptomatic patients than those in asymptomatic patients (Table1). Chest CT scanning revealed that among five children with lung lesions, three (60%) of them showing bilateral involvement in symptomatic children with no difference compared with asymptomatic children (p = 0.29, p = 0.64) (Table1). All patients received a combination therapy of interferon atomized inhalation with ribavirin, with a median hospital stays of 19.8 days. Discharge criteria were based on the Chinese Clinical Guidance for COVID-19 Pneumonia Diagnosis and Treatment (7th version).
Table 1

Clinical features, Laboratory tests, and CT scan of COVID-19 in symptomatic and asymptomatic children.

Median (IQR)
Normal rangeTotal (N = 10)Symptomatic (5,50%)Asymptomatic(5,50%)P
Age, median, y5.087.802.360.03
GenderM (3,30%)M (0,0%)M (3,60%)0.04
F (7,70%)F (5,100%)F (2,40%)
Clinical type0.29
Mild1,10%0,0%1,20%
Conventional9,90%5,100%4,80%
Time, days3.75 ± 5.916.60 ± 7.640.90 ± 0.220.17
Hospital stays19.80 ± 6.7021.60 ± 6.8818.00 ± 6.750.43



WBC × 109/L4−106.35 ± 2.774.55 ± 2.018.15 ± 2.280.03
N × 109/L2−71.85 ± 0.601.56 ± 0.382.14 ± 0.680.13
L × 109/L0.8−44.03 ± 2.262.56 ± 1.895.50 ± 1.590.03
M × 109/L0.12−0.80.35 ± 0.120.34 ± 0.150.36 ± 0.090.81
HBG110−150125.90 ± 7.85125.40 ± 9.89126.40 ± 6.350.45
PLT × 109/L100−300244.20 ± 89.69221.00 ± 47.19267.40 ± 120.530.72
ALT0−4024.80 ± 34.3213.00 ± 2.5536.60 ± 47.920.33
AST0−4031.30 ± 7.0925.80 ± 4.7636.80 ± 3.830.00
CRP0.068−8.21.38 ± 3.342.39 ± 4.740.37 ± 0.350.40
PCT0−0.050.05 ± 0.020.04 ± 0.020.05 ± 0.020.71
LDH109−245307.90 ± 92.47243.60 ± 23.11372.20 ± 91.490.03
CK26−14099.80 ± 45.5492.64 ± 29.07106.96 ± 60.760.65
Myo10−4611.67 ± 3.9912.47 ± 5.5710.87 ± 1.790.56
Ctn0−0.010.01 ± 0.000.01 ± 0.000.010.00
BUN2.9−8.24.25 ± 1.313.96 ± 0.914.54 ± 1.680.52
Cr50.4−98.144.61 ± 5.8347.64 ± 7.2441.58 ± 1.090.10
PT8.8−13.812.01 ± 0.5011.94 ± 0.6712.09 ± 0.330.68
D-dimer0−0.50.34 ± 0.200..39 ± 0.280.30 ± 0.060.54
IL-60−72.50 ± 2.493.30 ± 3.491.70 ± 0.450.34



Pneumonia9,90%5,100%4,80%0.29
CT (bilateral)6,66.7%3,60%3,75%0.64
CT (unilateral)3,33.3%2,40%1,40%

Note: Time: from onset to diagnosis.

Clinical features, Laboratory tests, and CT scan of COVID-19 in symptomatic and asymptomatic children. Note: Time: from onset to diagnosis.

Persistence of SARS-CoV-2 virus RNA in feces after discharge

All children returned to the Hospital for follow-up tests 2 weeks after discharge. Respiratory tract specimens, including throat swab, nose swab and sputum, and fecal specimens were examined for virus RNA. Some of the patients were also tested for virus RNA in urine samples. RT­PCR assay revealed negative results in the respiratory tract specimens and urine samples from all patients. In sharp contrast, seven of them contained SARS-CoV-2 virus RNA in fecal specimens. As a precaution, those seven patients, included three males (42.9%) with a median age of 4.69 years, were re-admitted for isolation and therapy. Were viewed the clinical data from the first hospitalization and found no difference in clinical features, laboratory findings, and chest CT findings between children showing positive and negative results in feces virus RNA tests (Table 2 ). Among those seven patients containing virus RNA in feces, six children showed no clinical symptoms, with normal laboratory tests and lung chest CT scanning. All seven patients received traditional Chinese medicine therapy in the 2nd hospitalization. The median time from onset to being negative results in respiratory tract and fecal specimens was 9 days and 34.43 days, respectively. The changing course in virus RNA detection of those seven patients is shown in Fig. 1 .
Table 2

Clinical features, Laboratory tests, and CT scan of COVID-19 in children with positive and negative results in stool specimens.

Median (IQR)
Normal rangeTotal (N = 10)Positive (7,70%)Negative (3,30%)p
Age, median, y5.084.696.000.68
GenderM (3,30%)M (3,42.9%)M (0,0%)0.18
F (7,70%)F (4,57.1%)F (3,100%)
Clinical type0.49
Mild1,10%1,14.3%0,0%
Conventional9,90%6,85.7%3,100%
symptomatic5,50%3,42.9%2,66.7%0.49
asymptomatic5,50%4,57.1%1,33.3%
Time, days3.75 ± 5.912.21 ± 1.787.33 ± 10.970.50
Hospital stays19.80 ± 6.7017.71 ± 4.6824.67 ± 9.240.14



Signs and symptoms
Fever4,40%3,42.9%1,33.3%0.78
Dry cough2,20%0,0%2,66.7%0.02
Phlegm1,10%0.0%1,33.3%0.11



WBC × 109/L4−106.35 ± 2.776.68 ± 2.775.60 ± 3.230.60
N × 109/L2−71.85 ± 0.601.89 ± 0.601.77 ± 0.740.79
L × 109/L0.8−44.03 ± 2.264.34 ± 2.273.30 ± 2.520.54
M × 109/L0.12−0.80.35 ± 0.120.31 ± 0.120.43 ± 0.060.15
HBG110−150125.90 ± 7.85125.57 ± 8.68126.67 ± 7.090.85
PLT × 109/L100−300244.2 ± 89.69237.0 ± 106.04261.00 ± 43.090.72
ALT0−4024.80 ± 34.3229.29 ± 41.0914.33 ± 1.150.56
AST0−4031.30 ± 7.0932.29 ± 7.5729.00 ± 6.580.53
CRP0.068−8.21.38 ± 3.341.86 ± 3.980.25 ± 0.110.52
PCT0−0.050.05 ± 0.020.04 ± 0.020.05 ± 0.020.57
LDH109−245307.9 ± 92.47302.14 ± 65.99321.33 ± 158.210.86
CK26−14099.80 ± 45.54101.97 ± 55.3594.73 ± 9.210.75
Myo10−4611.67 ± 3.9912.38 ± 4.4210.00 ± 2.650.42
Ctn0−0.010.01 ± 0.000.01 ± 0.000.010.00
BUN2.9−8.24.25 ± 1.314.53 ± 1.423.60 ± 0.870.33
Cr50.4−98.144.61 ± 5.8345.47 ± 6.9442.60 ± 0.360.51
PT8.8−13.812.01 ± 0.5012.02 ± 0.3612.00 ± 0.850.96
D-dimer0−0.50.34 ± 0.200..40 ± 0.200.21 ± 0.120.17
IL-60−72.50 ± 2.492.93 ± 2.941.50 ± 0.000.44



Pneumonia9,90%6,85.7%3,100%0.49
CT (bilateral)6,66.7%5,83.3%1,33.3%0.13
CT (unilateral)3,33.3%1,16.7%2,66.7%

Note: Time; from onset to diagnosis.

Fig. 1

The change course of 7 cases with positive results for COVID-19 in stool specimen.

Clinical features, Laboratory tests, and CT scan of COVID-19 in children with positive and negative results in stool specimens. Note: Time; from onset to diagnosis. The change course of 7 cases with positive results for COVID-19 in stool specimen.

Relapse of a patient with persistent SARS-CoV-2 virus RNA in feces after discharge

Among seven patients containing virus RNA in feces, one asymptomatic 11-month-old boy returned to the Hospital with fever, cough, nausea, vomiting, and diarrhea nine days after discharge. His clinical conditions were reassessed, as shown in Fig. 2 and Table 3. Virus RNA tests showed negative results in respiratory tract specimens (throat swab and sputum) but positive results in fecal specimens. Potential infection of other viruses such as influenza virus (A, B, H7 and N9 subtypes), EB virus, cytomegalovirus, enterovirus-71, coxsackie virus and enterovirus, or bacteria such as mycoplasma pneumoniae and chlamydia pneumoniae, were all considered and ruled out. The patient showed clinical symptoms of respiratory illness including fever, cough and mucus accumulation in the lung. CT scanning revealed the progression of lung inflammatory lesions compared to those during the 1st hospitalization (Fig. 2). During virus RNA detection by RT-PCR assays, the Ct value maintained in a similar level in readmittance compared with that previously confirmed (Fig. 3 ). There were also gastrointestinal symptoms such as nausea, vomiting, and diarrhea. The patient was readmitted for treatment with interferon atomization inhalation combined with cephalosporin antibiotics. Three days later, his temperature returned to a normal level, and he was discharged after 7-day hospital stay. Discharge criteria were based on the Chinese Clinical Guidance for COVID-19 Pneumonia Diagnosis and Treatment (7th version). The changing course in virus RNA detection is shown in Fig. 1 (#6 patient).
Fig. 2

Transverse chest CT images of case 6# with time.

Table 3

Clinical data of an 11 month old boy.

Normal rangeResult
Temperature38.7 °C
Heart rate145
Respiratory rate22



WBC × 109/L4−104.46
N × 109/L2−72.50
L × 109/L0.8−41.50
M × 109/L0.12−0.80.50
HBG110−150 g/L109
PLT × 109/L100−300229
ALT0−40 U/L20
AST0−40 U/L37
CRP0.068−8.2 mg/L1.08
PCT0−0.05 μg/L0.113
LDH109−245 U/L281
CK26−140 U/L376
BUN2.9−8.2 mmol/L6.0
Cr50.4−98.1 μmmol/L42.4
IL-60−7 pg/mL12.78



PneumoniaYes
CT (bilateral)Yes



StoolPositive
Throat swabNegative
SputumNegative



EBV-DNANegative
CMV-DNANegative
H7 ifuNegative
Ifu ANegative
Ifu BNegative
N9 ifuNegative
MpnNegative
CpnNegative
EV-71Negative
EVNegative
CA16Negative

Note: H7 ifu: H7 influenza virus; ifu A: influenza A; ifu B: influenza B; N9 ifu: N9 influenza virus; CMV: cytomegalovirus; EV-71: enterovirus-71; EV: enterovirus; CA-16: coxsackievirus-16.

Fig. 3

The change of Ct value of RT-PCR for COVID-19 in the stool specimen of case 6# with time.

Transverse chest CT images of case 6# with time. Clinical data of an 11 month old boy. Note: H7 ifu: H7 influenza virus; ifu A: influenza A; ifu B: influenza B; N9 ifu: N9 influenza virus; CMV: cytomegalovirus; EV-71: enterovirus-71; EV: enterovirus; CA-16: coxsackievirus-16. The change of Ct value of RT-PCR for COVID-19 in the stool specimen of case 6# with time.

Discussion

COVID-19 has been spreading worldwide and the pandemic is ongoing. According to the experience of China, the country with the earliest outbreak, all people are susceptible to SARS-CoV-2 [5]. By 10 March 2020, a total of ten children were admitted to the Jinan Infectious Disease Hospital Affiliated to Shandong University. Clinical and follow-up data of these patients were retrospectively analyzed. We observed that seven out of these ten patients were positive for SARS-CoV-2 virus RNA in fecal specimens within 2 weeks after discharge but were negative for respiratory tract specimens and urine samples. This suggests that the shedding time of the virus is longer in GI tract than that in respiratory tract of children. Several recent studies reported persistent fecal viral shedding in both adults and children. For example, 39 out of 73 patients with COVID-19 tested positive for SARS-CoV-2 virus RNA in stool samples and 17 patients remained positive for SARS-CoV-2 virus RNA in stool after becoming negative in respiratory samples [6]. Another study with the cohort of COVID-19 patients in Hong Kong reported that the pooled prevalence of positive SARS-CoV-2 virus RNA in stool samples was 48%, 70% of which still maintained positive after loss of virus in respiratory specimens [7]. A clinical study of pediatric patients with COVID-19 reported that eight of ten children persistently tested positive on rectal swabs after respiratory testing was negative [8]. A similar study also detected SARS-CoV-2 virus RNA in fecal specimens from an asymptomatic child when the nasopharyngeal test showed negative result [9], Experimental studies with animals infected with SARS-CoV-2 also detected viral RNA in feces of golden hamsters [10] and ferrets [11], suggesting that fecal viral shedding is a common feature of SARS-CoV-2 virus infection. The prolonged persistence of SARS-CoV-2 virus RNA in fecal specimens suggests a possibility of the existence of infectious virus in GI tract. Indeed, one recent study isolated alive virus, which could induce cytotoxicity effect in Vero E 6 cells, in stool sample of patients with COVID-19. However, it is worth noting that there is still insufficient evidence to support a transmission through the fecal-oral route in patients. ACE2 was confirmed to be a functional receptor for coronavirus [12], and is distributed in the lungs with age [[13], [14], [15]]. However, the relationship between distribution and aging in the small intestine and colon remains unclear. It is speculated that the number of ACE2 may be specifically distributed in the small intestine and colon of children. In addition, all children belonged to family clusters. Because of multi-member household infections, there is a high risk of viruses in household equipment. A previous study reported that samples from the toilet bowl, sink, and door handle were positive for nucleic acid even after cleaning [16]. Children have a characteristic of hyperactivity and not timely cleaning, and the likelihood of ingesting viral fragments is high. Finally, since children cannot effectively cough out airway secretions, there is also the possibility of a positive result in fecal specimens after swallowing. During the follow-up, six of the seven patients with a positive fecal test had no clinical symptoms, laboratory abnormalities, or abnormal lung CT finding. One child developed respiratory and GI symptoms and was re-admitted 9 days after discharge. As winter and spring have a high incidence of respiratory diseases, potential infection with virus such as influenza virus, EB virus, cytomegalovirus, enterovirus-71, coxsackievirus and enterovirus, or bacteria such as mycoplasma pneumoniae and chlamydia pneumoniae, were all considered. However, laboratory tests did not support these potential infections, but the Ct value of RT-PCR for COVID-19 in stool specimens of the case remained at a high level. Although positive RT-PCR result in fecal specimens cannot confirm the presence of live viruses, the possibility that the SARS-CoV-2 exists in the gut and induces a delayed inflammatory response cannot be ruled out.

Contributors

J.Y. took responsibility for the integrity of the data and the accuracy of the data analysis. J.Y. and X.L. had full access to all data in the study. H.C. contributed to RT-PCR assay. L.L. contributed to analysis on chest CT scanning. W.D. and Q.L. conceived the study and wrote the manuscript.

Funding

This study supported by Jinan Science and Technology Bureau (No.202001005).

Conflicts of interest

None declared.

Ethical approval

The project was approved by the ethics board of the Jinan Infectious Diseases Hospital (No.20200203).
  12 in total

1.  Characterization and significance of ACE2 and Mas receptor in human colon adenocarcinoma.

Authors:  Stella Bernardi; Cristina Zennaro; Silvia Palmisano; Elena Velkoska; Nicoletta Sabato; Barbara Toffoli; Greta Giacomel; Luigi Buri; Fabrizio Zanconati; Giuseppe Bellini; Louise M Burrell; Nicolò De Manzini; Bruno Fabris
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2011-11-02       Impact factor: 1.636

2.  Air, Surface Environmental, and Personal Protective Equipment Contamination by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) From a Symptomatic Patient.

Authors:  Sean Wei Xiang Ong; Yian Kim Tan; Po Ying Chia; Tau Hong Lee; Oon Tek Ng; Michelle Su Yen Wong; Kalisvar Marimuthu
Journal:  JAMA       Date:  2020-04-28       Impact factor: 56.272

3.  [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China].

Authors: 
Journal:  Zhonghua Liu Xing Bing Xue Za Zhi       Date:  2020-02-10

4.  Pathogenesis and transmission of SARS-CoV-2 in golden hamsters.

Authors:  Sin Fun Sia; Li-Meng Yan; Alex W H Chin; Kevin Fung; Ka-Tim Choy; Alvina Y L Wong; Prathanporn Kaewpreedee; Ranawaka A P M Perera; Leo L M Poon; John M Nicholls; Malik Peiris; Hui-Ling Yen
Journal:  Nature       Date:  2020-05-14       Impact factor: 49.962

5.  Gastrointestinal Manifestations of SARS-CoV-2 Infection and Virus Load in Fecal Samples From a Hong Kong Cohort: Systematic Review and Meta-analysis.

Authors:  Ka Shing Cheung; Ivan F N Hung; Pierre P Y Chan; K C Lung; Eugene Tso; Raymond Liu; Y Y Ng; Man Y Chu; Tom W H Chung; Anthony Raymond Tam; Cyril C Y Yip; Kit-Hang Leung; Agnes Yim-Fong Fung; Ricky R Zhang; Yansheng Lin; Ho Ming Cheng; Anna J X Zhang; Kelvin K W To; Kwok-H Chan; Kwok-Y Yuen; Wai K Leung
Journal:  Gastroenterology       Date:  2020-04-03       Impact factor: 22.682

6.  Infection and Rapid Transmission of SARS-CoV-2 in Ferrets.

Authors:  Young-Il Kim; Seong-Gyu Kim; Se-Mi Kim; Eun-Ha Kim; Su-Jin Park; Kwang-Min Yu; Jae-Hyung Chang; Eun Ji Kim; Seunghun Lee; Mark Anthony B Casel; Jihye Um; Min-Suk Song; Hye Won Jeong; Van Dam Lai; Yeonjae Kim; Bum Sik Chin; Jun-Sun Park; Ki-Hyun Chung; Suan-Sin Foo; Haryoung Poo; In-Pil Mo; Ok-Jun Lee; Richard J Webby; Jae U Jung; Young Ki Choi
Journal:  Cell Host Microbe       Date:  2020-04-06       Impact factor: 21.023

7.  Detection of Novel Coronavirus by RT-PCR in Stool Specimen from Asymptomatic Child, China.

Authors:  An Tang; Zhen-Dong Tong; Hong-Ling Wang; Ya-Xin Dai; Ke-Feng Li; Jie-Nan Liu; Wen-Jie Wu; Chen Yuan; Meng-Lu Yu; Peng Li; Jian-Bo Yan
Journal:  Emerg Infect Dis       Date:  2020-06-17       Impact factor: 6.883

8.  Evidence for Gastrointestinal Infection of SARS-CoV-2.

Authors:  Fei Xiao; Meiwen Tang; Xiaobin Zheng; Ye Liu; Xiaofeng Li; Hong Shan
Journal:  Gastroenterology       Date:  2020-03-03       Impact factor: 22.682

9.  Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis.

Authors:  I Hamming; W Timens; M L C Bulthuis; A T Lely; G J Navis; H van Goor
Journal:  J Pathol       Date:  2004-06       Impact factor: 7.996

10.  Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding.

Authors:  Yi Xu; Xufang Li; Bing Zhu; Huiying Liang; Chunxiao Fang; Yu Gong; Qiaozhi Guo; Xin Sun; Danyang Zhao; Jun Shen; Huayan Zhang; Hongsheng Liu; Huimin Xia; Jinling Tang; Kang Zhang; Sitang Gong
Journal:  Nat Med       Date:  2020-03-13       Impact factor: 87.241

View more
  16 in total

1.  Application of human RNase P normalization for the realistic estimation of SARS-CoV-2 viral load in wastewater: A perspective from Qatar wastewater surveillance.

Authors:  Shimaa S El-Malah; Jayaprakash Saththasivam; Khadeeja Abdul Jabbar; Arun K K; Tricia A Gomez; Ayeda A Ahmed; Yasmin A Mohamoud; Joel A Malek; Laith J Abu Raddad; Hussein A Abu Halaweh; Roberto Bertollini; Jenny Lawler; Khaled A Mahmoud
Journal:  Environ Technol Innov       Date:  2022-06-22

Review 2.  Pediatric Acute Severe Hepatitis of Unknown Origin: What is New?

Authors:  Jing Li; Wei Hu; Ji-Yuan Zhang; Fu-Sheng Wang
Journal:  J Clin Transl Hepatol       Date:  2022-06-20

Review 3.  A critical review on SARS-CoV-2 infectivity in water and wastewater. What do we know?

Authors:  Alexandre Giacobbo; Marco Antônio Siqueira Rodrigues; Jane Zoppas Ferreira; Andréa Moura Bernardes; Maria Norberta de Pinho
Journal:  Sci Total Environ       Date:  2021-02-09       Impact factor: 7.963

4.  Multiple relationships between aerosol and COVID-19: A framework for global studies.

Authors:  Yaxin Cao; Longyi Shao; Tim Jones; Marcos L S Oliveira; Shuoyi Ge; Xiaolei Feng; Luis F O Silva; Kelly BéruBé
Journal:  Gondwana Res       Date:  2021-02-09       Impact factor: 6.051

5.  Late incidence of SARS-CoV-2 infection in a highly-endemic remote rural village. A prospective population-based cohort study.

Authors:  Oscar H Del Brutto; Aldo F Costa; Robertino M Mera; Bettsy Y Recalde; Javier A Bustos; Héctor H García
Journal:  Pathog Glob Health       Date:  2020-09-29       Impact factor: 2.894

6.  Children's role in the COVID-19 pandemic: a systematic review of early surveillance data on susceptibility, severity, and transmissibility.

Authors:  Katy A M Gaythorpe; Sangeeta Bhatia; Tara Mangal; H Juliette T Unwin; Natsuko Imai; Gina Cuomo-Dannenburg; Caroline E Walters; Elita Jauneikaite; Helena Bayley; Mara D Kont; Andria Mousa; Lilith K Whittles; Steven Riley; Neil M Ferguson
Journal:  Sci Rep       Date:  2021-07-06       Impact factor: 4.379

Review 7.  Shedding of SARS-CoV-2 in feces and urine and its potential role in person-to-person transmission and the environment-based spread of COVID-19.

Authors:  David L Jones; Marcos Quintela Baluja; David W Graham; Alexander Corbishley; James E McDonald; Shelagh K Malham; Luke S Hillary; Thomas R Connor; William H Gaze; Ines B Moura; Mark H Wilcox; Kata Farkas
Journal:  Sci Total Environ       Date:  2020-07-31       Impact factor: 7.963

Review 8.  Coronavirus global pandemic: An overview of current findings among pediatric patients.

Authors:  Evanthia Perikleous; Aggelos Tsalkidis; Andrew Bush; Emmanouil Paraskakis
Journal:  Pediatr Pulmonol       Date:  2020-10-07

9.  Systematic review with meta-analysis: SARS-CoV-2 stool testing and the potential for faecal-oral transmission.

Authors:  Amarylle S van Doorn; Berrie Meijer; Chris M A Frampton; Murray L Barclay; Nanne K H de Boer
Journal:  Aliment Pharmacol Ther       Date:  2020-08-27       Impact factor: 9.524

10.  A case of gastrointestinal-predominant COVID-19 demonstrates value of stool PCR test.

Authors:  Neil C Khoury; Thomas J Russi
Journal:  J Med Virol       Date:  2020-09-29       Impact factor: 20.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.